COPENHAGEN, Feb 5 (Reuters) – Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group’s Wegovy pill at an introductory price of $49 per month.
“The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety,” the Danish drugmaker said in a statement.
“Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework,” it added.
Novo Nordisk said it was the only company that manufactured an FDA-approved Wegovy pill formulated with SNAC technology, which facilitates semaglutide absorption when administered orally.
(Reporting by Louise Rasmussen, editing by Anna Ringstrom)
About the Author
